BMS-933043

BMS-933043 is a potent and selective small molecule partial agonist of the alpha7 nicotinic acetylcholine receptor (α7 nAChR), developed by Bristol Myers Squibb for the treatment of central nervous system disorders, particularly cognitive deficits and negative symptoms associated with schizophrenia. The compound demonstrates high binding affinity and selectivity for α7 nAChRs over other nicotinic acetylcholine receptor subtypes and the 5-HT3A receptor. In preclinical models, BMS-933043 improved cognition and sensory processing measures relevant to schizophrenia. Despite promising preclinical results and completion of Phase I clinical trials in healthy volunteers, development for schizophrenia was discontinued after Phase I.[1][3][5][6][8]

Other names

(3R)-N-[6-(1H-imidazol-1-yl)-4-pyrimidinyl]spiro[1-azabicyclo[2.2.2]octane-3,5'(4'H)-oxazol]-2'-amine1221973-93-8